



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

#12  
NB  
06/03/02

Application of: **Yu, et al.**

Application Number: 09/589,288

Group Art Unit: 1646

Filed: June 8, 2000

Examiner: Prasad, S.

Title: **Methods of Treatment Using Antibodies** Atty. Docket No. PF343P3C5  
**to Neutrokin-alpha (as amended)**

**FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. §§ 1.56 and 1.97(c)**

Commissioner for Patents and Trademarks  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys/Agents for Applicants hereby direct the Examiner's attention to references B1-B5 listed on the attached revised form PTO/SB/08. Copies of references B6-B9 are submitted herewith.

Copies of references B1-B5 were submitted by Applicants or cited by the Examiner in connection with United States Patent Application Serial No. 09/005,874, filed January 12, 1998, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application Serial No. 09/005,874 for copies of references B1-B5. References B1-B4 were cited as references C1-C4 on the revised Form PTO/SB/08 submitted in the 09/005,874 application on January 25, 2002.

Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of this application are related to SEQ ID NOS:115536 and

197252 in copending U.S. Patent Application Serial No. 09/912,293. A legible copy of that portion of U.S. Patent Application Serial No. 09/912,293 which caused it to be listed on the attached revised form PTO/SB/08 was submitted by Applicants in connection with United States Patent Application Serial No. 09/005,874 on January 25, 2002 (as reference C1).


Identification of the listed reference is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such reference is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over the listed document should it be applied as a reference against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed reference and that the reference be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(c), since this information disclosure statement is being filed before the mailing date of a final action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application, a fee of \$180.00 is believed due in connection herewith. If Applicants are in error, please charge any additional required fees to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Respectfully submitted,

Date: May 3, 2002

  
\_\_\_\_\_  
Kenley K. Hoover (Reg. No. 40,302)  
Agent for Applicants

Human Genome Sciences, Inc.  
9410 Key West Avenue  
Rockville, MD 20850  
Telephone: (301) 610-5771

KKH/MS/vsr